- Details
- Art Rastinehad provides insight into the role of focal therapy in the treatment of prostate cancer. He begins the presentation with the evolution of prostate cancer care. He describes focal therapy in the context of the next significant opportunity in the treatment of prostate cancer once we have a positive biopsy and walks us through the why, the who the how and the where in defining focal therap...
|
- Details
- Alicia Morgans and Matt Cooperberg discuss the current state of contemporary active surveillance and efforts to standardize strategies nationwide. This conversation also includes discussion on informed decision making and practice patterns of active surveillance and how to tailor based on biology and genetics Biographies: Matthew Cooperberg, MD, MPH, FACS, Associate Professor, Department of Urolog...
|
- Details
- In this interview, Laurence Klotz discusses patients who have yet to be treated but have been diagnosed or in the process of being diagnosed with prostate cancer. Dr. Klotz reviews different case studies including treating a patient with mild elevation of PSA, age-adjusted norms, the use of a risk nomogram in determining significant cancer and deciding on a path of active surveillance. They also d...
|
- Details
- The 68Ga-PSMA PET/CT has a high clinical impact for preoperative staging, restaging biochemical recurrence after radical prostatectomy, and treatment monitoring. Dr. Chen highlights the details of this trial with two objectives. They assessed 68 Ga-PSMA PET/CT in primary prostate cancer with different clinical risks and further studied the inclusion of 11 C-Acetate PET/CT to see if there was an in...
|
- Details
- (Length of Interview: 20 min) John Feller is interviewed by John Fortin on laser focal therapy and focal laser ablation (FLA) therapy for the treatment in prostate cancer. He fields questions including his opinion on the typical candidate, availability and measuring side effects in FLA therapy. In addition, future plans to expand the scope in terms of the number of sites offering this therapy and...
|
- Details
- (Length of Presentation: 8 min) This presentation represents a study performed to assess if [18F]FDHT PET/CT could be a valuable imaging biomarker in patients with prostate cancer. Biographies: Gem Kramer, Radiology and Nuclear Medicine VU University Medical Center Amsterdam the Netherlands Read the Full Video Transcript {article title="assessment-of-simplified-methods-for-quantification-of-18f-fd...
|
- Details
- (Length of Discussion: 13 min) Todd Morgan shares the unique program that he and his GU team at the University of Michigan have implemented in an effort to gain a better understanding of the genetics and genomics involved with progression in prostate cancer. Biographies: Todd M. Morgan, M.D. is a urological surgeon specializing in the treatment of genitourinary malignancies and an Associate Profes...
|
- Details
- ( Length of Presentation 7 minutes) Christoph Rischpler presents a study aimed at investigating the PSMA-ligand uptake in PET in cervical, coeliac and sacral ganglia as a pitfall for lymph node metastases in prostate cancer imaging. This patient population consisted of 308 randomly selected patients who underwent Gallium 68 PSMA-PET between October 2012 and March 2014. For image analysis, they det...
|
- Details
- (Length of Discussion: 20 min) Alicia Morgans and David Penson discuss the relevance of Prostate Cancer Awareness Month and the importance of elevating the awareness for men and their respective caregivers about prostate cancer and other men's health issues and the need to be screened routinely for prostate cancer. Biographies: David F. Penson, MD, MPH, is the Paul V. Hamilton, M.D. and Virginia E...
|
- Details
- Alicia Morgans and Matt Cooperberg discuss the controversial topic of how to optimally screen for prostate cancer based on the final recommendations from the U.S. Preventive Services Task Force. Biographies: Matthew Cooperberg, MD, MPH, FACS, UCSF Helen Diller Family Comprehensive Cancer Center Alicia Morgans, MD, MPH Further Related Content: Biomarker Debate: Adopt, Expand, Trust (PRO) HPFS Healt...
|
